Supernus Pharmaceuticals

Supernus gives positive results from phase IIa trial for ADHD

Thursday, March 17, 2011

Supernus Pharmaceuticals reports its phase IIa US clinical trial of SPN-812 in adults for the treatment of attention deficit hyperactivity disorder (ADHD) met the primary endpoints of safety and tolerability and showed statistically significant median reduction versus placebo in both investigator-rated and patient-rated ADHD symptom scores. The trial was a randomized, double-blind, placebo-controlled trial in 52 adults with a current diagnosis of ADHD (26 subjects per treatment group).

[Read More]